OGN vs. BBIO, IONS, APLS, CYTK, BPMC, MDGL, ALPN, NUVL, ALKS, and PRGO
Should you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include BridgeBio Pharma (BBIO), Ionis Pharmaceuticals (IONS), Apellis Pharmaceuticals (APLS), Cytokinetics (CYTK), Blueprint Medicines (BPMC), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Organon & Co. (NYSE:OGN) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.
Organon & Co. presently has a consensus price target of $22.60, suggesting a potential upside of 5.02%. BridgeBio Pharma has a consensus price target of $48.00, suggesting a potential upside of 54.64%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Organon & Co..
Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
BridgeBio Pharma received 124 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 67.63% of users gave BridgeBio Pharma an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.
In the previous week, BridgeBio Pharma had 9 more articles in the media than Organon & Co.. MarketBeat recorded 16 mentions for BridgeBio Pharma and 7 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.77 beat BridgeBio Pharma's score of 0.70 indicating that Organon & Co. is being referred to more favorably in the media.
77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 1.2% of Organon & Co. shares are held by company insiders. Comparatively, 28.5% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Organon & Co. has a net margin of 16.50% compared to BridgeBio Pharma's net margin of -246.24%. BridgeBio Pharma's return on equity of 0.00% beat Organon & Co.'s return on equity.
Organon & Co. has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
Summary
BridgeBio Pharma beats Organon & Co. on 12 of the 19 factors compared between the two stocks.
Get Organon & Co. News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organon & Co. Competitors List
Related Companies and Tools
